Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter and full year ended December 31, 2011, and provided highlights of recent key developments.
“The approval and launch of BENLYSTA for systemic lupus in 2011 brings Human Genome Sciences closer to our long-standing goal of achieving profitability and sustained growth into the future,” said H. Thomas Watkins, President and Chief Executive Officer. “We have seen steady quarter-to-quarter progress with BENLYSTA sales, and we believe BENLYSTA is on its way to playing a major role in improving the standard of care for SLE patients.”
HGS reported revenues of $131.0 million for the year ended December 31, 2011, compared with revenues of $157.4 million for 2010. Revenues for 2011 included $52.3 million recognized from sales of BENLYSTA; $52.5 million recognized from sales and deliveries of raxibacumab to the U.S. Strategic National Stockpile; and $22.0 million recognized from manufacturing and development services other than raxibacumab. The decrease in revenues for 2011 reflected $82.8 million recognized from the ZALBIN agreement with Novartis in 2010.The Company reported a net loss for 2011 of $381.1 million ($1.97 per share), compared with a net loss of $233.2 million ($1.24 per share) for 2010. The increase in net loss was primarily due to increased selling, general and administrative expenses and increased commercial collaboration expenses related to the commercialization of BENLYSTA, partially offset by higher product sales revenue. As of December 31, 2011, cash and investments totaled $881.4 million, of which $801.2 million was unrestricted and available for operations. This includes $429.3 million in net cash from the Company’s successful public offering of Convertible Senior Notes completed in November 2011. This compares with cash and investments totaling $933.4 million as of December 31, 2010, of which $853.9 million was unrestricted and available for operations.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV